Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 7/20 | 0.49 |
| ▸ | NMT2 | O60551 | 6/20 | 0.49 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531769 | 0.97 | NMT1 (0.53) | NMT1NMT2SLC15A2FOLH1SLC6A5 | |
| SCHEMBL31757269 | 0.92 | NMT1 (0.51) | NMT1NMT2SLC15A2FOLH1SLC6A5 | |
| SCHEMBL32672545 | 0.91 | NMT1 (0.51) | NMT1NMT2SLC15A2FOLH1SLC6A5 | |
| SCHEMBL30455335 | 0.90 | NMT1 (0.50) | NMT1NMT2SLC15A2FOLH1SLC6A5 | |
| SCHEMBL30932293 | 0.89 | FOLH1 (0.49) | NMT1NMT2SLC15A2FOLH1SLC6A5 | |
| SCHEMBL30397555 | 0.89 | NMT1 (0.53) | NMT1NMT2SLC15A2SLC6A5TLR2 | |
| SCHEMBL30398397 | 0.89 | NMT1 (0.53) | NMT1NMT2SLC15A2SLC6A5TLR2 | |
| SCHEMBL29606164 | 0.89 | NMT1 (0.56) | NMT1NMT2SLC15A2SLC6A5CPB2 | |
| SCHEMBL29532146 | 0.89 | SLC15A2 (0.58) | NMT1NMT2SLC15A2FOLH1SLC6A5 | |
| SCHEMBL31213154 | 0.88 | SLC6A5 (0.45) | NMT1NMT2SLC15A2SLC6A5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807899-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited | 2023-11-07 | — | — | US | disclosed |
| CN-110669146-B | Active peptide capable of specifically blocking binding site of adapter protein Nck for preventing intestinal EPEC infection | 常州大学 | 2023-05-23 | — | — | CN | disclosed |
| US-20220273830-A1 | COMPOUNDS AND METHODS OF USE | Edinburgh Molecular Imaging Limited (GB) | 2022-09-01 | — | — | US | disclosed |
| US-20220145378-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-05-12 | — | — | US | disclosed |
| EP-3983019-A1 | COMPOUNDS AND METHODS OF USE | Edinburgh Molecular Imaging Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| EP-3773750-B1 | FORMULATION AND METHOD OF PREPARATION | GE HEALTHCARE AS (NO) | 2022-04-20 | — | — | EP | disclosed |
| CN-114222592-A | Compounds and methods of use | 爱丁堡分子成像有限公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273830-A1 | COMPOUNDS AND METHODS OF USE | VIP, QPCT, CALCRL | NMT1 179/4885NMT2 145/4885SLC15A2 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.